Victory Capital Management Inc Cel Sci Corp Transaction History

Victory Capital Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 01, 2021	SELL	$11.05 - $16.62 $172,402 - $259,305	-15,602 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$11.69 - $14.54 $5,669 - $7,051	-485 Reduced 3.01%	15,602 $199,000
Q2 2020 Aug 07, 2020	BUY	$9.75 - $17.6 $95,355 - $172,128	9,780 Added 155.07%	16,087 $240,000
Q1 2020 May 04, 2020	BUY	$7.54 - $17.05 $731 - $1,653	97 Added 1.56%	6,307 $73,000
Q4 2019 Feb 04, 2020	BUY	$6.71 - $9.55 $946 - $1,346	141 Added 2.32%	6,210 $81,000
Q3 2019 Nov 12, 2019	BUY	$6.0 - $9.6 $36,414 - $58,262	6,069 New	6,069 $54,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $28.6M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.